University of California, Los Angeles
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, Los Angeles sits in the top decile of US sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count).
University of California, Los Angeles: 897 sponsored US clinical trials, 158 recruiting.
University of California, Los Angeles sponsors 897 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 622 completed. 98 of these trials are in Phase 3-4 (later-stage) and 194 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 17 trials.
Top-decile sponsor footprint
University of California, Los Angeles ranks in the top decile of sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
622 of 679 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
897 total, page 7 of 18
Transcutaneous (Tragus) Vagal Nerve Stimulation for Post-op Afib
NCT04514757
Pilot Evaluation of Together for Wellness Website in COVID-19
NCT04961242
Effects of Biofeedback on Somatic Symptoms
NCT05120648
Mobile-enhanced Group CBT for Adolescents at Risk Severe Mood Disorders
NCT04887155
Discrimination and the Brain-Gut-Microbiome (BGM) Axis
NCT05120908
An Electronic Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions
NCT04851691
Decreasing Intraoperative Skin Damage in Prone Position Surgeries
NCT04884737
Overactive Bladder Telemedicine Non-inferiority Trial
NCT05117918
Cognitive and Biological Responses in Stress
NCT05026333
Using Behavioral Economics to Reduce Low-Value Care
NCT04104256
Acupressure for COVID-19 Related Quality of Life and Stress
NCT04472559
Cognitive Intervention to Improve Working Memory
NCT03687008
Investigating Immune Escape by SARS-CoV-2 Variants
NCT05171803
Telerehabilitation Early After Stroke
NCT04657770
Specialized Pacing for Patients With Congenital Heart Disease
NCT03361189
Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding
NCT04878614
Evaluating BOSCC and ELSA as Outcome Measures in the Context of a JASPER Intervention Trial
NCT04146428
Reducing Intracranial atheroSclErosis With Repatha
NCT04573777
New Moms Mood Tracking & Wellbeing
NCT05056454
Investigation of Cinnamon Spice on Glucose Tolerance in Subjects With Pre-diabetes
NCT04342624
Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers
NCT05279053
Dual Energy Cone-Beam Computed Tomography (DE-CBCT) Assessment of Jaw Bone Density
NCT04686084
iCBT With TMS in Patients With MDD
NCT05988619
Contingency Management for PrEP Adherence and/or Methamphetamine Use
NCT04563962
Quantifying Body Composition and Liver Disease in Children Using Free-Breathing MRI and MRE
NCT04591106
Text-based Reminders to Promote COVID-19 Vaccinations
NCT04801524
Text-based Interventions to Promote COVID-19 Vaccinations
NCT04800965
Dance for Children With Autism
NCT04762290
Triamcinolone Packing Following Endoscopic Sinus Surgery
NCT04841343
Heparin Prophylaxis Dosing for Antepartum Hospitalizations (HEPDOSE)
NCT04635839
Pediatric Second Influenza Dose Portal Reminder Recall
NCT04668417
A Study to Evaluate the Effect of Vagus Nerve Stimulation in Patients Undergoing VT Ablation
NCT04359004
Community-based Adaptive Autism Intervention for Toddlers
NCT04283045
Transcranial Direct Current Stimulation (tDCS) Therapy in Major Depression
NCT04507243
Optimization of VNS in Epileptic Patients to Induce Cardioprotection
NCT04387435
UTECH: Machine Learning for HIV Prevention Among Substance Using GBMSM
NCT04710901
Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test
NCT04904510
Media Project and Health Study - Spanish Version
NCT04862624
Health and Health Care Utilization Effects of Medical Debt Forgiveness
NCT04835012
Donor Breast Milk and Breastfeeding Rates
NCT04572581
Revefenacin in Acute Respiratory Insufficiency in COPD
NCT04315558
TSC Remote Assessment and Intervention
NCT04698538
Mindfulness-based Intervention to Address PTSD in Trauma-exposed, Homeless Women
NCT04605198
The Effect of Grape Consumption on Increasing the Good Bacteria in the Human Intestine
NCT05025189
Study of Dietary Composition in Crohn's Disease
NCT04431700
Acute Effects of TCIG vs ECIG in PLWH
NCT04568395
Using Behavioral Science to Improve Colorectal Cancer Screening Rates With Mailed FIT Kits
NCT04746469
Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- UCLA Portal R/R Influenza RCT 3
NCT04533685
Harnessing Generativity Among Young Adult Cancer Survivors
NCT04272346
PED NEONAT 20-000599 Fetal Body Composition
NCT04508751
What is open in the University of California, Los Angeles pipeline
158 recruiting of 897 indexed (18% open); 622 completed (69%).
Phase mix: 98 late (III/IV) vs 194 early (I/II) (early-phase heavy).
Top condition: Depression (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, Los Angeles: open-pipeline peers nationwide
Peers matched on 897 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 897 trials (± recruiting share)
- Indiana University · 890 trials · 18% recruiting
- Hoffmann-La Roche · 909 trials · 8% recruiting
- Brigham and Women's Hospital · 937 trials · 15% recruiting
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
Sponsors near 18% open enrollment (± trial volume)
- ConvaTec · 18% recruiting · 17 trials
- Endologix · 18% recruiting · 17 trials
- National Institute on Deafness and Other Communication Disorders (NIDCD) · 18% recruiting · 34 trials
- NICHD Pelvic Floor Disorders Network · 18% recruiting · 17 trials
Related
What to do with this University of California, Los Angeles page
897 registered trials is a research-attention snapshot, not an endorsement of University of California, Los Angeles or any single study.
- 158 of University of California, Los Angeles's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition University of California, Los Angeles studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, Los Angeles pipeline card: 897 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.